Shots:
Biogen has entered into a definitive agreement to acquire RayThera, expanding its immunology pipeline
As per the deal, Biogen will acquire RayThera for ~$1B, incl. an upfront payment & clinical and regulatory milestone payments; closing is expected in Q3’26
Following closing, Biogen will lead development, manufacturing & global commercialization of RayThera’s assets, incl. the…
